

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Smyth 1



Section 1.							
Section 1.	Identifying Inform	ation					
1. Given Name (Fii Elizabeth	rst Name)	2. Surname (Last Na Smyth	me)		3. Date 30-May-2020		
4. Are you the cor	responding author?	✓ Yes No					
5. Manuscript Title Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients							
6. Manuscript lder	6. Manuscript Identifying Number (if you know it)						
Section 2.	The Work Under Co	ancideration for D	ublication				
	The work under Co	onsideration for P	ublication				
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to gra			commercial, private founda design, manuscript prepara		
Section 3.	Dalamat Caracial	and the contract of the	de e le estre d				
	Relevant financial activities outside the submitted work.						
of compensation	n) with entities as descri	oed in the instructio	ns. Use one line fo	or each entity	relationships (regardless r; add as many lines as yo s months prior to publi c	ou need by	
Are there any rel	evant conflicts of intere	st? ✓ Yes	No				
If yes, please fill o	out the appropriate info	rmation below.					
Name of Entity		Grant? Personal	Non-Financial	Other? C	omments		
rtaine or Entiry		Fees?	Support?	Other			
Astellas							
Astrazeneca							
BMS							
Celgene							
Five Prime Therapeut	tics						
Gritstone Oncology							
Merck							
Servier							

Smyth 2



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Comments		
Zymeworks					
Section 4. Intellectual Propert	y Patents & Cop	yrights			
Do you have any patents, whether plann	ed, pending or issued	d, broadly relevan	nt to the work? Yes	✓ No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote i			nfluenced, or that give the	appearance of	
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				disclosure statements.	
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this form below.		enerate a disclosi	ure statement, which will a	appear in the box	
Dr. Smyth reports personal fees from As Celgene, personal fees from Five Prime T personal fees from Servier, personal fees	herapeutics, persona	al fees from Gritst	one Oncology, personal fe		

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Smyth 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above. 5.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Alsina 1



Section 1. Identifying Information	ation					
1. Given Name (First Name) Maria	2. Surname (Last Name) 3. Date Alsina 19-June-2020					
4. Are you the corresponding author?	Are you the corresponding author?					
5. Manuscript Title Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients						
6. Manuscript Identifying Number (if you know it) ATM-20-4725						
Section 2. The Work Under Co	nsideration for F	Publication				
Did you or your institution at any time received any aspect of the submitted work (including lest statistical analysis, etc.)? Are there any relevant conflicts of interest	ve payment or service but not limited to gra	s from a third party			c.) for	
Section 3. Relevant financial activities outside the submitted work.						
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should repart there any relevant conflicts of interesting the second conflicts of interesting	oed in the instruction ort relationships the st? Yes	ns. Use one line fo	or each entity	y; add as many lines as you need	d by	
Name of Entity	Grant? Persona Fees?	Non-Financial Support?	Other? C	comments		
MSD				entific consultancy, honoraria for eaking		
BMS				ntific consultancy, honoraria for eaking		
Servier				ntific consultancy, honoraria for eaking		
illy				ntific consultancy, honoraria for		

Alsina 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Alsina reports personal fees from MSD, personal fees from BMS, personal fees from Servier, personal fees from Lilly, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Alsina 3